AXSM Shariah Compliance
Screening Methodology: AAOIFI
As of July 2026, Axsome Therapeutics Inc is classified as halal.
HALAL
Report Source: 2026 1st Quarter Report
Axsome Therapeutics Inc. Stock Analysis AXSM
United States Health Care Large Cap Report: Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. The company is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Read More Axsome Therapeutics Inc (AXSM) Chart
Key Statistics of Axsome Therapeutics Inc (AXSM)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$235.69Volume
776.41KP/E Ratio (TTM)
-52 Week Range
Market Cap
12.64BAvg. Volume
1.23MDividend Yield
-Financial Metrics & Statements of Axsome Therapeutics Inc (AXSM)
Super Investors Invested in Axsome Therapeutics Inc (AXSM)
FAQ's for Axsome Therapeutics Inc (AXSM)
- As of July 2026, Axsome Therapeutics Inc AXSM is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Axsome Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Axsome Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Axsome Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Axsome Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Axsome Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.